Pimpri-Chinchwad
08048038652
How Genetic Testing Can Help Identify Inherited Cancer Risk

A cancer diagnosis in one relative can raise questions about whether other family members inherited a higher-risk gene change. By reviewing family-history clues, test types, preparation steps, and result meanings, you can understand when to seek genetic counselling and what a result can—and cannot—tell you.

Key takeaways

  • A pathogenic germline variant raises risk but does not diagnose cancer.
  • Ask for counselling when cancer occurs young, repeatedly, or across one family line.
  • Positive results guide screening and help relatives decide whether to test.
  • A negative or uncertain result does not always eliminate inherited risk.

What does inherited cancer risk mean, and when should you seek counselling?

Inherited cancer risk starts with a pathogenic germline variant: a DNA change present throughout the body and sometimes passed through a family. This differs from a cancer-causing change found only in a tumour, called a somatic variant. A pathogenic variant increases susceptibility; it does not diagnose cancer or mean cancer is inevitable.

Risk depends on the gene, variant, age, sex, family history of cancer and other factors.

Seek genetic counselling if your history includes:

  • Breast cancer diagnosed at a young age
  • Ovarian, fallopian-tube, primary peritoneal or pancreatic cancer
  • Male breast cancer
  • Cancer in both breasts, or multiple primary cancers in one person
  • Several close relatives with breast, ovarian, pancreatic, prostate, colorectal or related cancers
  • A distinctive ancestry pattern linked with hereditary cancer syndromes
  • A known familial mutation

A genetic counsellor reviews your personal history and a three-generation family history before recommending testing. Limited information does not rule out inherited cancer risk. Relatives may have been adopted, died young, belonged to a small family, or had incomplete medical records, leaving a hereditary pattern hidden.

Even without a strong family history, counselling can be appropriate when the cancer type, age at diagnosis or tumour findings raises concern.

Which genes and genetic tests can reveal inherited risk?

The key distinction is whether the DNA change is present throughout your body or only in the cancer. Germline testing uses blood or saliva to look for inherited variants; somatic tumour testing examines cancer tissue and mainly guides treatment.

Test typeSample and purposeWhat the result can show
Germline testingBlood or saliva; inherited DNAA pathogenic variant passed through a family
Somatic tumour testingCancer tissue; tumour profilingTreatment-relevant changes or findings that suggest Lynch syndrome
Confirmatory testingBlood or saliva after a tumour findingWhether the change is inherited rather than tumour-only

A tumour result does not prove inheritance. Abnormal mismatch-repair immunohistochemistry or microsatellite-instability testing can suggest Lynch syndrome, but non-inherited tumour changes can produce the same signal.

A targeted single-gene test fits a known family variant or a strongly suspected syndrome.

A hereditary cancer panel checks several genes, including BRCA1 and BRCA2 for breast, ovarian, fallopian-tube, primary peritoneal, pancreatic and prostate cancer risk; PALB2; MLH1, MSH2, MSH6, PMS2 and EPCAM for Lynch syndrome; APC for familial adenomatous polyposis; TP53 for Li-Fraumeni syndrome; and CDH1 for hereditary diffuse gastric and lobular breast cancer.

Broader genomic testing covers more genes but increases the chance of uncertain findings that cannot guide care.

Testing an affected relative first is often most informative. If it identifies a pathogenic variant, relatives can receive a focused test for that exact change instead of navigating an inconclusive broad panel.

What happens during genetic testing, and how should you prepare?

Genetic testing starts with a three-generation family history, followed by referral to a genetic counsellor or qualified clinician. After informed consent, you provide a blood or saliva sample. The laboratory analyses selected genes, then a clinician explains the genetic test report and its limits.

Prepare these records before the appointment:

  • Pathology reports
  • Death certificates, where available
  • Exact cancer diagnoses, not only “abdominal cancer” or “female cancer”
  • Ages at diagnosis
  • Records of bilateral cancers or multiple primary cancers
  • Relatives’ genetic test reports
  • Ancestry information

If a relative reportedly “tested positive,” obtain the original report. The laboratory needs the exact gene and variant, not a verbal summary; without those details, it cannot perform reliable targeted testing for the familial finding.

Ask these questions before consenting:

QuestionWhy it matters
Which genes are included?The panel determines what the test can and cannot detect.
How are uncertain findings handled?A variant of uncertain significance should not direct surgery or screening.
Who will explain the result?Interpretation requires personal and family context.
Does the laboratory reclassify variants?Classifications can change as evidence develops.
How will amended reports reach me?Updated findings need clinical review before changing care.

How should you interpret positive, negative and uncertain results?

A positive genetic test identifies a pathogenic or likely pathogenic variant in a gene linked to inherited cancer susceptibility. It does not show that cancer is present, and it does not make cancer inevitable. It can support gene-specific surveillance, discussion of risk-reducing surgery, and targeted testing for blood relatives.

A negative genetic test is most informative when the laboratory specifically looked for a known familial variant and did not find it. If no family mutation has been identified, “negative” means no currently detectable pathogenic variant was found in the tested genes; those genes may not explain the family history.

Strong family history can still justify increased surveillance.

A variant of uncertain significance (VUS) is a genetic change whose cancer-risk effect is not established. Do not use it to choose preventive surgery, irreversible treatment, or major screening changes. Follow personal and family history until the laboratory reclassifies the finding.

Use the report to confirm these decisions:

  • Ask which gene and exact variant produced the result, and whether it is pathogenic, likely pathogenic, benign, or uncertain.
  • Ask what surveillance applies to your age, sex, gene and family history.
  • Share a positive result with relatives through genetic counselling so they can consider targeted testing.
  • Arrange periodic clinical review. A VUS can later be downgraded to benign or upgraded, and an amended report should not change care without review.

How can an inherited result change care for you and your relatives?

An inherited result informs care; it does not prescribe treatment by itself. The cancer type, stage, previous treatment, overall health, exact gene and variant determine whether the finding changes the plan.

FindingPossible care implicationWhat determines it
BRCA1, BRCA2 or another DNA-repair findingA targeted systemic treatment or clinical-trial option may be relevantCancer type, stage, prior treatment and the specific pathogenic variant
Mismatch repair or microsatellite instability findingImmune-checkpoint therapy may be consideredWhether the result is inherited or tumour-based, plus the cancer and treatment history
Known familial pathogenic variantFamilial mutation testing can identify relatives who carry the same changeThe exact gene and variant named in the laboratory report

Share the complete laboratory report—not a verbal summary—with blood relatives through genetic counselling. This gives them the gene, variant and laboratory classification needed for informed cascade testing, while counselling addresses uncertainty, emotional effects and reproductive questions.

A relative who does not carry the known familial variant generally does not need carrier-specific surveillance, but standard population screening still applies. If no familial variant was identified, family history can still justify closer assessment.

In Pimpri-Chinchwad, Dr Gawande Oncocare Centre can review the report alongside your diagnosis, staging and treatment plan; bring every page, including the variant classification and testing method.

Frequently asked questions

  • What does inherited cancer risk mean?

    It means a pathogenic germline variant is present throughout the body and can be passed through a family. It increases susceptibility but does not mean cancer is inevitable.

  • When should you seek genetic counselling for cancer risk?

    Seek counselling when cancer occurs at a young age, affects several relatives, appears in multiple generations, involves rare cancers, or includes related cancers such as breast and ovarian cancer.

  • Which genes can genetic testing identify?

    Testing can examine genes linked to inherited cancer syndromes, such as BRCA1, BRCA2, TP53, MLH1, MSH2, MSH6, PMS2 and APC. The appropriate panel depends on your personal and family history.

  • What happens during inherited cancer genetic testing?

    A counsellor reviews your history, explains possible results and obtains consent. Testing usually uses a blood or saliva sample, followed by a report and a discussion of what the result means.

  • What do positive, negative and uncertain genetic results mean?

    A positive result identifies a pathogenic variant and can change screening and family testing. A negative result finds no tested pathogenic variant but may not remove unexplained family risk. A variant of uncertain significance should not guide medical decisions until its classification changes.

Oct 27th, 2026 1:01 PM